Down-Regulation of HLA Class I Antigen Processing Molecules: An Immune Escape Mechanism of Renal Cell Carcinoma?
- 1 February 2004
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 171 (2), 885-889
- https://doi.org/10.1097/01.ju.0000094807.95420.fe
Abstract
Purpose: Proper HLA class I antigen processing and presentation is a prerequisite for the recognition of tumor cells by cytotoxic T lymphocytes. To date there exist only limited information on the expression of components of the HLA class I associated antigen processing machinery (APM) in surgically removed benign renal cell adenoma, and primary and metastatic renal cell carcinoma (RCC). Materials and Methods: A total of 133 primary RCCs of different subtypes, 10 renal cell adenoma biopsies, 32 matched metastases of different localization and autologous normal kidney epithelium were immunohistochemically analyzed for the expression of HLA class I antigens, low molecular weight protein (LMP)2 and LMP7, the transporter associated with antigen processing subunit (TAP1) and β2-microglobulin (β2-m). Results: Normal kidney tissue showed strong cytoplasmic staining intensity for LMP2, LMP7 and TAP1, whereas β2-m and HLA class I heavy chains were detected on the cell surface. A low frequency of HLA class I HC and β2-m down-regulation was found in RCC. In contrast, primary RCC and metastases showed a high frequency of a total lack of heterogeneous TAP1, LMP2 and LMP7 expression, which was often coordinately regulated. APM component deficiencies were associated with RCC subtypes but not with tumor grading and staging. Conclusions: HLA class I APM component abnormalities appear to represent an immune escape mechanism of RCC. This finding emphasizes the need to evaluate the integrity and expression of these molecules in patients with RCC, especially in those selected for treatment with T-cell based immunotherapy.Keywords
This publication has 17 references indexed in Scilit:
- Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapiesThe Lancet Oncology, 2003
- Novel therapies for renal cell carcinoma – an updateExpert Opinion on Investigational Drugs, 2003
- Tapasin—the keystone of the loading complex optimizing peptide binding by MHC class I molecules in the endoplasmic reticulumMolecular Immunology, 2002
- Therapeutic options in the management of renal cell carcinomaSeminars in Oncology, 2002
- Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathwaysMolecular Immunology, 2002
- Immune gene therapy in urologyCurrent Urology Reports, 2002
- The Transporter Associated With Antigen Processing (TAP): Structural Integrity, Expression, Function, and Its Clinical RelevanceMolecular Medicine, 2001
- DEGRADATION OF CELL PROTEINS AND THE GENERATION OF MHC CLASS I-PRESENTED PEPTIDESAnnual Review of Immunology, 1999
- RENAL CELL CARCINOMA: MANAGEMENT OF ADVANCED DISEASEJournal of Urology, 1999
- Cancer statistics, 1998CA: A Cancer Journal for Clinicians, 1998